Navigation Links
Drug developed by Hebrew U. and others holds promise for treatment of wounds
Date:2/7/2011

Jerusalem, February 7, 2011 -- A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

Diabetes is a rapidly growing medical problem affecting close to 3 percent of the world's population. Poor blood circulation arising from diabetes often results in skin wounds which do not heal, causing pain, infection and at times amputation of limbs.

Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they do not last long on the injured site.

Now, scientists at the Hebrew University and Harvard involved in the project have used genetic engineering to produce a "robotic" growth factor protein that responds to temperature. Increasing the temperature causes dozens of these proteins to fold together into a nanoparticle that is more than 200 times smaller than a single hair.

This behavior greatly simplifies protein purification, making it very inexpensive to produce. It also enables the growth factor to be confined and to remain at the burn or wound site. The scientists refer to their discovery as robotic, since just as robots are machines that respond to their environment by carrying out a specific activity, so too this protein they have developed responds and reacts to heat.

The experimental drug, which ha been developed by the research group as a topical ointment, has been patented and thus far has been used to treat chronic wounds in diabetic mice, dramatically increasing the healing rate. The goal is to proceed to human clinical trials at some future date after future tests and refinements.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Page: 1

Related biology technology :

1. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
2. Neurochip technology developed by Canadian team
3. The European HEALTHGRAIN consortium developed a definition for whole grain
4. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
5. New Program Developed in the Fight Against Feline Aids
6. New nanotech sensor developed with medical, chemistry applications
7. New lab-on-a-chip technique developed at U of T
8. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
9. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
10. New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
11. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug developed by Hebrew U. and others holds promise for treatment of wounds
(Date:4/19/2017)... ... 2017 , ... Optofluidics today announced that it's changing its ... changed focus to making analytical tools for biopharmaceutical quality control. “We are excited ... Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered the ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... ... Clostridium difficile (C. diff) infections through education and advocacy. Founded in 2010 ... to a C. diff infection, the foundation has become the most-consulted source for ...
(Date:4/19/2017)... , April 19, 2017  As a ... and Heroin Summit ,  Proove® Biosciences, Inc. ... genetics, environmental, and lifestyle factors to accurately predict ... University of Southern California (USC), the Interventional Pain ... Proove publish results showing that Proove Opioid Risk® ...
(Date:4/19/2017)... WALTHAM, Mass. , April 19, 2017 /PRNewswire/ ... that results from the multi-center Procalcitonin MOnitoring SEpsis ... 2017 print issue of Critical Care Medicine ... Predicts Mortality in Severe Sepsis Patients: Results From ... the use of the B·R·A·H·M·S PCT (procalcitonin) assay ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):